These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 10463605)
1. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Yamori T; Matsunaga A; Sato S; Yamazaki K; Komi A; Ishizu K; Mita I; Edatsugi H; Matsuba Y; Takezawa K; Nakanishi O; Kohno H; Nakajima Y; Komatsu H; Andoh T; Tsuruo T Cancer Res; 1999 Aug; 59(16):4042-9. PubMed ID: 10463605 [TBL] [Abstract][Full Text] [Related]
2. A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism. Matsuba Y; Edatsugi H; Mita I; Matsunaga A; Nakanishi O Cancer Chemother Pharmacol; 2000; 46(1):1-9. PubMed ID: 10912571 [TBL] [Abstract][Full Text] [Related]
3. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986 [TBL] [Abstract][Full Text] [Related]
4. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles. Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485 [TBL] [Abstract][Full Text] [Related]
5. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606 [TBL] [Abstract][Full Text] [Related]
6. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity. Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548 [TBL] [Abstract][Full Text] [Related]
7. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Yamori T Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S74-9. PubMed ID: 12819939 [TBL] [Abstract][Full Text] [Related]
8. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Kobayashi E; Okamoto A; Asada M; Okabe M; Nagamura S; Asai A; Saito H; Gomi K; Hirata T Cancer Res; 1994 May; 54(9):2404-10. PubMed ID: 8162588 [TBL] [Abstract][Full Text] [Related]
9. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of fluorenhymustine as a rationally designed novel anticancer agent. Samanta S; Pain A; Ghosh M; Dutta S; Sanyal U Exp Oncol; 2005 Dec; 27(4):279-85. PubMed ID: 16404347 [TBL] [Abstract][Full Text] [Related]
11. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II. Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662 [TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor activity of bizelesin in mice. Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280 [TBL] [Abstract][Full Text] [Related]
13. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998 [TBL] [Abstract][Full Text] [Related]
14. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Lorusso D; Mainenti S; Pietragalla A; Ferrandina G; Foco G; Masciullo V; Scambia G Expert Opin Investig Drugs; 2009 Dec; 18(12):1939-46. PubMed ID: 19938904 [TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy and molecular mechanism of TLK58747, a novel DNA-alkylating prodrug. Xu H; Wang Z; Donaldson JC; Yao H; Zhou S; Kelson AB; Ma W; Weber KT; Laborde E; Cheng M; Sambucetti L; Keck JG Anticancer Res; 2009 Oct; 29(10):3845-55. PubMed ID: 19846918 [TBL] [Abstract][Full Text] [Related]
16. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners. Beria I; Baraldi PG; Cozzi P; Caldarelli M; Geroni C; Marchini S; Mongelli N; Romagnoli R J Med Chem; 2004 May; 47(10):2611-23. PubMed ID: 15115402 [TBL] [Abstract][Full Text] [Related]
17. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898 [TBL] [Abstract][Full Text] [Related]
18. Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes. Buckley RG; Elsome AM; Fricker SP; Henderson GR; Theobald BR; Parish RV; Howe BP; Kelland LR J Med Chem; 1996 Dec; 39(26):5208-14. PubMed ID: 8978849 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro and in vivo antitumor activity of 2-phenylpyrroloquinolin-4-ones. Ferlin MG; Chiarelotto G; Gasparotto V; Dalla Via L; Pezzi V; Barzon L; Palù G; Castagliuolo I J Med Chem; 2005 May; 48(9):3417-27. PubMed ID: 15857148 [TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance. Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]